

Progress in neuroprotective strategies for preventing epilepsy

Munjal M. Acharya^{a,b}, Bharathi Hattiangady^{a,b}, Ashok K. Shetty^{a,b,*}

^a Medical Research and Surgery Services, Veterans Affairs Medical Center, Durham, NC 27705, United States

^b Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, United States

Received 6 April 2007; received in revised form 9 September 2007; accepted 26 October 2007

Abstract

Neuroprotection is increasingly considered as a promising therapy for preventing and treating temporal lobe epilepsy (TLE). The development of chronic TLE, also termed as epileptogenesis, is a dynamic process. An initial precipitating injury (IPI) such as the status epilepticus (SE) leads to neurodegeneration, abnormal reorganization of the brain circuitry and a significant loss of functional inhibition. All of these changes likely contribute to the development of chronic epilepsy, characterized by spontaneous recurrent motor seizures (SRMS) and learning and memory deficits. The purpose of this review is to discuss the current state of knowledge pertaining to neuroprotection in epileptic conditions, and to highlight the efficacy of distinct neuroprotective strategies for preventing or treating chronic TLE. Although the administration of certain conventional and new generation anti-epileptic drugs is effective for primary neuroprotection such as reduced neurodegeneration after acute seizures or the SE, their competence for preventing the development of chronic epilepsy after an IPI is either unknown or not promising. On the other hand, alternative strategies such as the ketogenic diet therapy, administration of distinct neurotrophic factors, hormones or antioxidants seem useful for preventing and treating chronic TLE. However, long-term studies on the efficacy of these approaches introduced at different time-points after the SE or an IPI are lacking. Additionally, grafting of fetal hippocampal cells at early time-points after an IPI holds considerable promise for preventing TLE, though issues regarding availability of donor cells, ethical concerns, timing of grafting after SE, and durability of graft-mediated seizure suppression need to be resolved for further advances with this approach. Overall, from the studies performed so far, there is consensus that neuroprotective strategies need to be employed as quickly as possible after the onset of the SE or an IPI for considerable beneficial effects. Nevertheless, ideal strategies that are capable of facilitating repair and functional recovery of the brain after an IPI and preventing the evolution of IPI into chronic epilepsy are still hard to pin down.

© 2007 Elsevier Ltd. All rights reserved.

Keywords: Aberrant synaptic reorganization; Anti-epileptic drugs; Antioxidants; Dentate gyrus; Dentate neurogenesis; GABA-ergic interneurons; Head injury; Hippocampus; Hippocampal cell grafts; Hormones; Ketogenic diet; Learning and memory deficits; Mossy fiber sprouting; Neural cell transplants; Neural stem cells; Neurodegeneration; Neurotrophic factors; Spontaneous seizures; Status epilepticus; Synaptic plasticity; Temporal lobe epilepsy

Abbreviations: AAT, aspartate aminotransferase; AACOT, acetoacetyl-CoA thiolase; Ad-GDNF, adenoviral vector derived glial cell line derived neurotrophic factor; AED, anti-epileptic drug; AKG, alpha keto glutarate; aFGF, acidic fibroblast growth factor; BBB, blood brain barrier; BDA, biotinylated dextran amine; BDNF, brain derived neurotrophic factor; bFGF (FGF-2), basic fibroblast growth factor or fibroblast growth factor-2; BHB, beta hydroxy butyrate; cAMP, cyclic adenosine mono phosphate; CNS, central nervous system; CR, calorie restricted; CS, citrate synthetase; CREB, cAMP responsive element binding protein; Cyt c, cytochrome c; DCX, doublecortin; DG, dentate gyrus; DH, dentate hilus; DHEA, dehydroepiandrosterone; DSGL, dentate supragranular layer; EEG, electroencephalogram; EPO, erythropoietin; EPSP, excitatory post-synaptic potential; ERK, extracellular-signal-regulated kinase; FBM, felbamate; GABA, gamma amino butyric acid; GABA_A, GABA receptor A subtype; GAD, glutamic acid decarboxylase; GAT-1, GABA transporter type 1; GBP, gabapentin; GCL, granule cell layer; GDNF, glial cell derived neurotrophic factor; Gln, glutamine; ICV KA, intracerebroventricular kainic acid; IPI, initial precipitating injury; IP KA, intraperitoneal kainic acid; IPSP, inhibitory post-synaptic potential; KA, kainic acid; KD, ketogenic diet; LDH, lactate dehydrogenase; LEV, levetiracetam; LDL, low density lipoprotein; LPS, lipopolysaccharide; LTP, long-term potentiation; MAPK, mitogen-activated protein kinase; MPT, mitochondrial permeability transition pore; NGF, nerve growth factor; NMDA, N-methyl-D-aspartate; NO, nitric oxide; NPY, neuropeptide Y; NSC, neural stem/progenitor cells; NTF, neurotrophic factor; NT-3, neurotrophin-3; OAA, oxaloacetate; OGD, oxygen-glucose deprivation; PHB, Phenobarbital; PI3K, Phosphatidylinositol-3-kinase; PNS, Peripheral nervous system; PROG, progesterone; PREG, pregnenolone; PREGS, pregnenolone sulfate; PTZ, pentelenetetrazole; PDH, pyruvate dehydrogenase; rhGDNF, recombinant human GDNF; ROS, reactive oxygen species; SCOT, succinyl-CoA transferase; SE, status epilepticus; SGZ, subgranular zone; SLM, stratum lacunosum moleculare; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum; SRMS, spontaneous recurrent motor seizures; TCA, tricarboxylic acid; TGB, tiagabine; TGF- β , transforming growth factor beta; TLE, temporal lobe epilepsy; TPM, topiramate; UCP, uncoupling protein; VEGF, vascular endothelial growth factor; VGB, vigabatrin; VPA, valproic acid; 3-OH-butyrate, 3-hydroxy-butyrate.

* Corresponding author at: Division of Neurosurgery, Box 3807, Duke University Medical Center, Durham, NC 27710, United States. Tel.: +1 919 286 0411x7096.

E-mail address: ashok.shetty@duke.edu (A.K. Shetty).

Contents

1.	Introduction	365
2.	Definition, causes and consequences of seizures	365
3.	Hippocampal neurodegeneration and synaptic reorganization after seizures	365
3.1.	Abnormal sprouting of mossy fibers in the dentate gyrus	366
3.2.	Abnormal sprouting of entorhinal axons in the CA1 subfield	367
3.3.	Sprouting of CA3 axons	367
4.	Changes in GABA-ergic interneurons after seizures	367
4.1.	Alterations in hippocampal interneurons	369
4.2.	Alterations in entorhinal cortex interneurons	371
5.	Dentate neurogenesis and temporal lobe epilepsy	371
6.	Neuroprotective strategies for preventing chronic epilepsy	372
7.	Neuroprotection using anti-epileptic drugs	373
7.1.	Conventional anti-epileptic drugs	373
7.1.1.	Benzodiazepines	373
7.1.2.	Phenobarbital	373
7.1.3.	Valproate	374
7.2.	New anti-epileptic drugs	374
7.2.1.	Topiramate	374
7.2.2.	Felbamate	375
7.2.3.	Levetiracetam	375
7.2.4.	Gabapentin	375
7.2.5.	Lamotrigine	375
7.2.6.	Tiagabine	376
7.2.7.	Vigabatrin	376
7.3.	Conclusions	376
8.	Neuroprotection using the ketogenic diet	376
8.1.	Neuroprotective and disease modifying effects of the ketogenic diet	376
8.2.	Metabolic effects of ketogenic diet therapy	377
8.3.	Effects of ketogenic diet on mitochondrial function	377
8.4.	Effects of ketogenic diet on seizure induced apoptosis	378
8.5.	Clinical relevance of ketogenic diet therapy	378
8.6.	Conclusions	379
9.	Neuroprotection via administration of neurotrophic factors	379
9.1.	Potential of fibroblast growth factors	380
9.2.	Potential of neurotrophins as neuroprotective agents	380
9.2.1.	Usefulness of the brain-derived neurotrophic factor	380
9.2.2.	Efficacy of Nerve growth factor	382
9.2.3.	Effectiveness of neurotrophin-3	382
9.3.	Efficiency of glial cell line derived neurotrophic factor	382
9.4.	Usefulness of the vascular endothelial growth factor	383
9.5.	Conclusions	383
10.	Efficacy of antioxidants as neuroprotective compounds against epilepsy	383
10.1.	Resveratrol	383
10.2.	Curcumin	384
10.3.	Conclusions	384
11.	Hormones and neuroprotection	385
11.1.	Potential of estrogens	385
11.2.	Efficacy of progesterone	385
11.3.	Efficiency of other neurosteroids	386
11.4.	Usefulness of erythropoietin	386
11.5.	Melatonin as a neuroprotectant	386
11.6.	Conclusions	387
12.	Neuroprotective effects of neural cell transplants	387
12.1.	Efficacy of fetal cell grafting for hippocampal repair after injury	387
12.1.1.	Graft cell survival and graft-host connectivity	389
12.1.2.	Effect of fetal hippocampal cell grafting on the number of host GABA-ergic interneurons	389
12.1.3.	Effect of fetal hippocampal cell grafting on aberrant sprouting of host mossy fibers	389
12.1.4.	Effect of fetal hippocampal cell grafting on calbindin expression	390
12.1.5.	Efficacy of neural cell grafting for preventing SE-induced development of chronic seizures	390
12.2.	Additional cell grafting studies that are relevant to preventing TLE after an IPI	390

Download English Version:

<https://daneshyari.com/en/article/4353737>

Download Persian Version:

<https://daneshyari.com/article/4353737>

[Daneshyari.com](https://daneshyari.com)